Sacubitril

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

Sacubitril/valsartan failed to demonstrate significant reverse remodeling effect compared with valsartan among patients with asymptomatic left ventricular systolic dysfunction following MI, a speaker reported.

The PARALLAX trial of sacubitril/valsartan for HF with preserved ejection fraction met one of its two co-primary endpoints, showing a reduction in NT-proBNP, but no additional benefit on 6-minute walk distance and functional class.

Sacubitril/valsartan was superior to valsartan alone for reduction of renal events in patients with HF and preserved ejection fraction and chronic kidney disease, researchers reported.